About this trial
Patients over the age of 65 years are at increased risk for developing delirium after noncardiac surgeries, resulting in increased morbidity and mortality. The prevention of postoperative delirium has been classified as a public health priority. However, so far data regarding possible intraoperative interventions to reduce the incidence of postoperative delirium is very scarce. Due to the more rapid wash-in and wash-out times of desflurane as compared to sevoflurane or propofol it seems reasonable that desflurane might be beneficial for the prevention of postoperative delirium. Therefore, we evaluate the effect of maintenance of anesthesia using desflurane, sevoflurane or propofol on postoperative delirium in elderly patients undergoing moderate- to high-risk major noncardiac surgery.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Provide written informed consent
≥65 years of age
Scheduled for elective major noncardiac surgery with estimated time of surgery ≥ 2 hours
Disqualifiers
Patients undergoing emergency surgery
BMI > 45 kg/m²
History of diagnosed dementia
Language, vision, or hearing impairments that may compromise cognitive assessments
Trial design
Parallel
Treatments tested in this trial
Desflurane
DrugAfter induction of anesthesia, maintenance of anesthesia will be performed using goal-directed administration of desflurane with an intraoperative goal of bispectral index (BIS) 50±10.
Sevoflurane
DrugAfter induction of anesthesia, maintenance of anesthesia will be performed using goal-directed administration of sevoflurane with an intraoperative goal of bispectral index (BIS) 50±10.
Propofol
DrugAfter induction of anesthesia, maintenance of anesthesia will be performed using goal-directed administration of propofol with an intraoperative goal of bispectral index (BIS) 50±10.
Treatment groups
Trial outcomes
Primary outcomes
Incidence of postoperative delirium
Delirium will be assessed via 3D-cognitive assessment method (3D-CAM) test as early in the morning as practical and in the early evening for the initial five postoperative days while the patients remain hospitalized according to current recommendations. In patients in the intensive care unit (ICU), we will perform the 3D-CAM-ICU. Any positive CAM test will be considered evidence of delirium, which will be analyzed dichotomously.
Secondary outcomes
Digit Symbol-Substitution-Test for the incidence of postoperative cognitive dysfunction (POCD)
POCD will be assessed using the Digit-Symbol-Substitution-Test (DSST). The occurrence of POCD will be defined when a patient has a Z score on two or all tests or the combined Z score is below -1.96 standard deviation (SD).
Trail Making Test (TMT) for the incidence of postoperative cognitive dysfunction (POCD)
POCD will be assessed using the Trail Making Test (TMT). The occurrence of POCD will be defined when a patient has a Z score on two or all tests or the combined Z score is below -1.96 standard deviation (SD).
Postoperative need of supplemental oxygen
We will record postoperative need for administration of supplemental oxygen to maintain a SpO2 of 93% during PACU or ICU stay.
Length of stay in ICU
Length of stay in ICU after surgery.
Other outcomes
Days at home in the first month after surgery
Number of days at home within the first 30 postoperative days.
Long-term postoperative cognitive dysfunction
Long-term postoperative cognitive dysfunction will be assessed via Montreal cognitive assessment (MoCA). We will assess the baseline MoCA a day before surgery and one year after surgery via phone interview. Minimum score of the MoCA is 0 points. Maximum score of the MoCA is 22 points. Postoperative cognitive dysfunction is defined as a reduction of at least 2 points as compared to baseline.
Postoperative IL-6 concentrations (pg/ml)
Postoperative area under the curve (AUC) within the first two postoperative days of concentrations of Interleukin 6 (IL-6).
Postoperative PCT concentrations (ng/ml)
Postoperative area under the curve (AUC) within the first two postoperative days of concentrations of Procalcitonin (PCT).
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Medical University of Vienna
Lead sponsor
Medical University Innsbruck
Collaborator